Generate Biomedicines, Inc.
NASDAQ:GENBAsset Management
+$0.13 today
- Market cap
- $1.34B
- Beta
- 0.19
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$4.06
Volume 1.05M
Average 0.55M
GENB Sales of Investments
Cash received from selling or redeeming investments.
Generate Biomedicines, Inc.NASDAQ: GENB
Sales of Investments · Q1 FY2026 · quarter ended Mar 2026
Sales of investments of $65M in Q1 FY2026
Q1 FY2026 sales of investments was $65M.
Context
- Sales of investments amounted to 893.7% of revenue in FY2025, down 224.2 pp from a year earlier.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 285.01M USD
- Year-over-year change
- +24.6%
- 1-year CAGR
- +24.6%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 285.01M | +24.6% |
| FY2024 | 2024-12-31 | 228.69M | — |
Sales of Investments vs competitors
How GENB compares with its peers on the latest reported figures
- GENB's FY2025 sales of investments of $285.01M is the largest of the 5 companies compared; the peer median is $159.76M.
- Its year-over-year change of +24.6% is the highest of 4, against a peer median of -56.8%.
- Sales of investments amounts to 893.7% of revenue for GENB, versus a peer median of 315.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
GENBGenerate Biomedicines, Inc. | FY2025 | $285.01M | +24.6% | — | 893.7% |
| LTM Mar 2026 | $263.81M | -56.8% | +18.0% | 264.9% | |
| LTM Sep 2026 | $249.02M | -57.5% | -0.3% | 367.0% | |
| LTM Mar 2026 | $70.5M | -52.5% | +140.4% | 3839.9% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding GENB) | $159.76M | -56.8% | +18.0% | 315.9% | |
Competitors are the stored peer set for GENB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Net Income | (181.38M) | (222.97M) |
| Depreciation & Amortization | 15.35M | 13.18M |
| Deferred Income Tax | 0 | 0 |
| Stock-Based Compensation | 19.47M | 20.58M |
| Change in Working Capital | 28.12M | (14.62M) |
| Accounts Receivables | (213K) | 308K |
| Inventory | 0 | 0 |
| Accounts Payables | 3.5M | (2.13M) |
| Other Working Capital | 24.83M | (12.79M) |
| Other Non-Cash Items | 702K | 3.21M |
| Operating Cash Flow | (117.75M) | (200.62M) |
| Capital Expenditures | (3.45M) | (3.51M) |
| Acquisitions (Net) | 0 | 0 |
| Purchases of Investments | (282.98M) | (164.73M) |
| Sales of Investments | 228.69M | 285.01M |
| Other Investing Activities | 10K | 0 |
| Investing Cash Flow | (57.73M) | 116.77M |
| Debt Repayment | (11.12M) | (8.16M) |
| Common Stock Issued | 0 | 0 |
| Common Stock Repurchased | 0 | 0 |
| Dividends Paid | 0 | 0 |
| Other Financing Activities | 6.13M | 14.25M |
| Financing Cash Flow | 91.33M | 28.06M |
| Effect of Forex Changes | 0 | 0 |
| Net Change in Cash | (84.15M) | (55.79M) |
| Free Cash Flow | (121.2M) | (204.13M) |
Generate Biomedicines, Inc.
NASDAQ:GENB
Intrinsic Alpha fair value
Locked
Current Price
$10.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.